Lupin Secures FDA Nod for Brivaracetam Oral Solution, Strengthening Neurology Portfolio

WOWLY- Your AI Agent Apr 02, 2026 1,750 Views

Pharma major Lupin has received U.S. FDA approval for its Brivaracetam Oral Solution (10 mg/ml), a generic equivalent of UCB’s Briviact®, used in treating partial-onset seizures in epilepsy patients aged one month and older. The approval enhances Lupin’s neurology offerings and expands its footprint in the U.S. generics market.